Global Non-Proliferative Diabetic Retinopathy Market Trends and Future Outlook to 2029
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Are The Market Size Estimates For The Non-Proliferative Diabetic Retinopathy Market?
There has been robust growth in the non-proliferative diabetic retinopathy market size in the past few years. It is projected to expand from $2.62 billion in 2024 to $2.83 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 8.1%. This growth during the historic period can be credited to a rise in diabetes cases, an aging populace, enhanced awareness, advancements in research, alterations in lifestyles, and better management of diabetes.
Expectations are high for substantial growth in the non-proliferative diabetic retinopathy market in the coming years. It is predicted to increase to $3.77 billion in 2029, with a compound annual growth rate (CAGR) of 7.4%. This projected growth during the forecast period can be linked to a variety of factors such as the adoption of telemedicine, advancements in therapeutic treatments, incorporation of artificial intelligence, escalating investment in research and development, and a broadening of healthcare infrastructure. Key trends to watch in this period involve a rise in the utilization of artificial intelligence for screening and diagnostic purposes, an expanding demand for telemedicine and remote patient monitoring systems, the introduction of personalized strategies for treating diabetic retinopathy, an increasing emphasis on prevention and early intervention, and an enlarged role of patient-centered care models in managing diabetic retinopathy.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15620&type=smp
What Drivers Are Accelerating Expansion Of The Non-Proliferative Diabetic Retinopathy Market?
The growth of the non-proliferative diabetic retinopathy market is projected to be driven by the mounting prevalence of diabetes. Often characterized by high blood sugar levels as a result of insufficient insulin production or resistance to its effects, diabetes is a chronic metabolic disorder. Factors such as inactive lifestyles, poor eating habits, and genetic factors contribute to its cause. The condition leads to non-proliferative diabetic retinopathy by harmfully affecting retinal blood vessels, mainly from prolonged exposure to excessively high blood glucose levels, causing visual impairment and possibly blindness. For example, in June 2024, the National Health Service, a UK government entity, discovered that in 2023, there were an additional 549,000 individuals at risk of developing type 2 diabetes in England. This resulted in a total of 3,615,330 people registering non-diabetic hyperglycemia, or pre-diabetes, with a GP, a significant rise from the 3,065,825 recorded in 2022, marking an approximate 20% increase. Consequently, the escalating incidence of diabetes is fuelling the expansion of the non-proliferative diabetic retinopathy market.
What Are The Key Segment Trends Observed In The Non-Proliferative Diabetic Retinopathy Market?
The non-proliferative diabetic retinopathymarket covered in this report is segmented –
1) By Treatment Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy; Intraocular Steroid Injection; Laser Surgery; Vitrectomy
2) By Disease Severity Level: Mild Non-Proliferative Diabetic Retinopathy; Moderate Non-Proliferative Diabetic Retinopathy; Severe Non-Proliferative Diabetic Retinopathy
3) By End-User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Other End-Users
Subsegments:
1) By Anti-Vascular Endothelial Growth Factor (Vegf) Therapy: Bevacizumab (Avastin); Ranibizumab (Lucentis); Aflibercept (Eylea); Pegaptanib (Macugen)
2) By Intraocular Steroid Injection: Triamcinolone Acetonide; Dexamethasone Implant (Ozurdex); Fluocinolone Acetonide Implant (Iluvien)
3) By Laser Surgery: Focal Laser Photocoagulation; Panretinal Photocoagulation
4) By Vitrectomy: Pars Plana Vitrectomy (Ppv); Membrane Peeling Vitrectomy; Phaco-Vitrectomy (Combined Cataract And Vitrectomy Surgery)
Which Disruptive Trends Are Driving Change Across The Non-Proliferative Diabetic Retinopathy Market?
Leading firms in the non-proliferative diabetic retinopathy segment are integrating AI technology into their cameras to enhance patient results and push forward ophthalmic imaging. These AI-empowered cameras are infused with artificial intelligence algorithms that help in obtaining, evaluating, and understanding images of the eye for both diagnostic and treatment reasons. For instance, in May 2024, Optomed, a medical technology company from Finland, introduced the Optomed Aurora AEYE. This handheld AI fundus camera was specifically designed for immediate detection of more than just mild diabetic retinopathy. The device ingeniously merges the mobility of a handheld camera with the capabilities of artificial intelligence. This leads to the production of superior retinal images utilized for early detection and tracking of various eye diseases. The Optomed Aurora AEYE uses AI algorithms to help medical professionals interpret retinal images, facilitating the prompt and precise identification of ailments such as diabetic retinopathy, glaucoma, and age-related macular degeneration.
Who Are The Major Stakeholders Operating In The Non-Proliferative Diabetic Retinopathy Market?
Major companies operating in the non-proliferative diabetic retinopathy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Abbott Laboratories, Novartis AG, Eli Lilly and Company, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Genentech Inc., Carl Zeiss Meditec AG, ZEISS Group, Santen Pharmaceutical Co. Ltd., Santen Inc., Topcon Corporation, Lumenis Ltd., Alimera Science, Ocular Therapeutix Inc., Acucela Inc., Ampio Pharmaceuticals, Kowa Company Ltd., Nidek Co. Ltd.
Access The Complete Report Here:
What Regional Factors Are Accelerating Growth In The Non-Proliferative Diabetic Retinopathy Market?
North America was the largest region in the non-proliferative diabetic retinopathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-proliferative diabetic retinopathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=15620&type=smp
Browse Through More Reports Similar to the Global Non-Proliferative Diabetic Retinopathy Market 2025, By The Business Research Company
Diabetic Foot Ulcer Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/diabetic-foot-ulcer-global-market-report
Proliferative Diabetic Retinopathy Pdr Global Market Report 2025
Diabetic Gastroparesis Treatment Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
